Q/C Technologies, Inc. Deferred Other Tax Expense (Benefit)
Q/C Technologies, Inc. (QCLS) reported Deferred Other Tax Expense (Benefit) of $1.96 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredOtherTaxExpenseBenefit · last filed 2021-03-01
- Q/C Technologies, Inc. deferred other tax expense (benefit) for fiscal 2020 was $1.96M, a 165.31% increase from fiscal 2019.
- Q/C Technologies, Inc. deferred other tax expense (benefit) for fiscal 2019 was $738.00K, a 74.91% decline from fiscal 2018.
- Q/C Technologies, Inc. deferred other tax expense (benefit) for fiscal 2018 was $2.94M, a 51.01% decline from fiscal 2017.
- Q/C Technologies, Inc. deferred other tax expense (benefit) for fiscal 2017 was $6.00M, a 699.33% increase from fiscal 2016.
| Period end | Deferred Other Tax Expense (Benefit) 12 month | Deferred Other Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2020-12-31 | $1.96M 10-K · filed 2021-03-01 | |
| 2019-12-31 | $738.00K 10-K · filed 2021-03-01 | |
| 2018-12-31 | $2.94M 10-K · filed 2020-03-25 | |
| 2017-12-31 | $6.00M 10-K · filed 2019-04-01 | $6.44M 10-K · filed 2018-04-03 |
| 2016-12-31 | $751.00K 10-K/A · filed 2018-07-13 | |
| 2015-12-31 | -$3.80M 10-K · filed 2017-04-11 | |
| 2014-12-31 | -$1.43M 10-K · filed 2016-03-30 | |
| 2013-12-31 | -$940.00K 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |